Table 3. NRTI susceptibility of WT and mutant HIV-1 RT.
The concentrations of NRTI required to inhibit the activity of purified RT by 50% (IC50) are reported as an average of three independent experiments±S.D. Values in parentheses indicate fold-resistance
| IC50 (μM) | |||
|---|---|---|---|
| ddTTP | AZT-TP | d4T-TP | |
| WT | 0.10±0.05 (1.0) | 0.06±0.01 (1.0) | 0.20±0.02 (1.0) |
| I132A | 0.07±0.02 (0.7) | 0.02±0.01 (0.3) | 0.13±0.03 (0.7) |
| I132M | 0.06±0.01 (0.6) | 0.03±0.01 (0.5) | 0.12±0.04 (0.6) |
| I135A | 0.08±0.02 (0.8) | 0.04±0.01 (0.6) | 0.16±0.05 (0.8) |
| I135M | 0.09±0.03 (0.9) | 0.06±0.01 (1.0) | 0.17±0.05 (0.9) |
| N136A | * | ||
| N137A | 0.10±0.04 (1.0) | 0.06±0.02 (1.0) | 0.18±0.04 (0.9) |
| E138A | 0.09±0.02 (0.9) | 0.03±0.01 (0.5) | 0.16±0.06 (0.8) |
| E138K | 0.10±0.03 (1.0) | 0.07±0.02 (1.2) | 0.16±0.06 (0.8) |
| T139A | * | ||
| T139V | 0.10±0.05 (1.0) | 0.06±0.02 (1.0) | 0.14±0.06 (0.7) |
| P140A | * | ||
* RT activity too low to effectively evaluate NRTI susceptibility.